{"filing":{"accession_number":"0001193125-26-396752","cik":"0001585608","ticker":"JAGX","company_name":"Jaguar Health, Inc.","form":"8-K","filing_date":"2026-09-21","report_date":"2026-09-15","primary_document":"d79729d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1585608/000119312526396752/d79729d8k.htm"},"events":[{"id":34049,"run_id":31342,"accession_number":"0001193125-26-396752","anchor_item_number":"8.01","event_type":"governance_other","event_domain":"governance","is_material":true,"confidence":0.75,"summary":"Jaguar Health completed a 1-for-15 reverse stock split effective September 17, 2026, reducing outstanding shares from approximately 7.8 million to 520,088. The reverse split modified security holder rights and the company's capital structure, with details disclosed across Items 3.03 and 8.01.","company_name":"Jaguar Health, Inc.","ticker":"JAGX","filing_date":"2026-09-21","form":"8-K","submitted_at":null,"items":[{"id":37672,"accession_number":"0001193125-26-396752","item_number":"3.03","item_title":null,"event_type":"governance_other","event_domain":"governance","is_material":true,"confidence":0.75,"reasoning":"Item 3.03 discloses a material modification to security holder rights through a reverse stock split. The filing incorporates details from Item 8.01, indicating a structural change to the equity capital that affects all shareholders' ownership percentages and voting rights. Reverse stock splits are governance events that modify the terms of outstanding securities and are material to investors assessing share structure and potential delisting risk mitigation.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-21T20:48:41.304036+00:00","company_name":"","ticker":null,"filing_date":""},{"id":37674,"accession_number":"0001193125-26-396752","item_number":"8.01","item_title":null,"event_type":"governance_other","event_domain":"governance","is_material":true,"confidence":0.75,"reasoning":"The disclosure reports completion of a 1-for-15 reverse stock split effected on September 17, 2026, reducing outstanding shares from approximately 7.8 million to 520,088. While a reverse split is a capital structure event with governance implications, it is not a named event type in the taxonomy. This is a governance-related disclosure (affecting share structure and potentially listing compliance) that does not fit exec_appointment, exec_departure, exec_compensation, or shareholder_vote_results, making governance_other the most appropriate classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-21T20:48:41.304036+00:00","company_name":"","ticker":null,"filing_date":""}]},{"id":34050,"run_id":31342,"accession_number":"0001193125-26-396752","anchor_item_number":"5.03","event_type":"governance_other","event_domain":"governance","is_material":false,"confidence":0.85,"summary":"Jaguar Health filed a Certificate of Elimination with Delaware removing multiple series of preferred stock from its Certificate of Incorporation and returning those shares to authorized but undesignated preferred stock. This was a routine housekeeping amendment following the conversion or disposition of all outstanding shares of the specified preferred series.","company_name":"Jaguar Health, Inc.","ticker":"JAGX","filing_date":"2026-09-21","form":"8-K","submitted_at":null,"items":[{"id":37673,"accession_number":"0001193125-26-396752","item_number":"5.03","item_title":null,"event_type":"governance_other","event_domain":"governance","is_material":false,"confidence":0.85,"reasoning":"This disclosure describes the filing of a Certificate of Elimination with Delaware that removed multiple series of preferred stock from the Company's Certificate of Incorporation and returned those shares to authorized but undesignated preferred stock. The filing is a routine corporate governance matter—a technical amendment to the capital structure following the conversion or disposition of all outstanding shares of the specified preferred series. No shares were outstanding at the time of filing, making this a housekeeping amendment rather than a material capital event.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-21T20:48:41.304036+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":37672,"accession_number":"0001193125-26-396752","item_number":"3.03","item_title":null,"event_type":"governance_other","event_domain":"governance","is_material":true,"confidence":0.75,"reasoning":"Item 3.03 discloses a material modification to security holder rights through a reverse stock split. The filing incorporates details from Item 8.01, indicating a structural change to the equity capital that affects all shareholders' ownership percentages and voting rights. Reverse stock splits are governance events that modify the terms of outstanding securities and are material to investors assessing share structure and potential delisting risk mitigation.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-21T20:48:41.304036+00:00","company_name":"Jaguar Health, Inc.","ticker":"JAGX","filing_date":"2026-09-21"},{"id":37673,"accession_number":"0001193125-26-396752","item_number":"5.03","item_title":null,"event_type":"governance_other","event_domain":"governance","is_material":false,"confidence":0.85,"reasoning":"This disclosure describes the filing of a Certificate of Elimination with Delaware that removed multiple series of preferred stock from the Company's Certificate of Incorporation and returned those shares to authorized but undesignated preferred stock. The filing is a routine corporate governance matter—a technical amendment to the capital structure following the conversion or disposition of all outstanding shares of the specified preferred series. No shares were outstanding at the time of filing, making this a housekeeping amendment rather than a material capital event.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-21T20:48:41.304036+00:00","company_name":"Jaguar Health, Inc.","ticker":"JAGX","filing_date":"2026-09-21"},{"id":37674,"accession_number":"0001193125-26-396752","item_number":"8.01","item_title":null,"event_type":"governance_other","event_domain":"governance","is_material":true,"confidence":0.75,"reasoning":"The disclosure reports completion of a 1-for-15 reverse stock split effected on September 17, 2026, reducing outstanding shares from approximately 7.8 million to 520,088. While a reverse split is a capital structure event with governance implications, it is not a named event type in the taxonomy. This is a governance-related disclosure (affecting share structure and potentially listing compliance) that does not fit exec_appointment, exec_departure, exec_compensation, or shareholder_vote_results, making governance_other the most appropriate classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-21T20:48:41.304036+00:00","company_name":"Jaguar Health, Inc.","ticker":"JAGX","filing_date":"2026-09-21"}]}